NCT02918032 International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases
| NCT ID | NCT02918032 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
| Condition | Neutral Lipid Storage Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2014-01 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2014-01 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to understand the state of onset of NLSD(neutral lipid storage disease) / TGCV(triglyceride deposit cardiovasculopathy) worldwide, background information of affected patients, and natural history of the disease, as well as exploring the prognostic factors and assessing the efficacy of disease-specific treatment.
Eligibility Criteria
Inclusion Criteria: * Patients who are diagnosed with NLSD / TGCV Exclusion Criteria: * None
Contact & Investigator
Kenichi Hirano, MD, Ph.D
📞 +81-6-6872-8215
Kenichi Hirano, MD, Ph.D
PRINCIPAL INVESTIGATOR
Department of Cardiovascular Medicine, Faculty of Internal Medicine, Graduate School of Osaka University
Frequently Asked Questions
Who can join the NCT02918032 clinical trial?
This trial is open to participants of all sexes, studying Neutral Lipid Storage Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02918032 currently recruiting?
Yes, NCT02918032 is actively recruiting participants. Visit ClinicalTrials.gov or contact Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan to inquire about joining.
Where is the NCT02918032 trial being conducted?
This trial is being conducted at Stanford, United States, New York, United States, Graz, Austria, Beijing, China and 11 additional locations.
Who is sponsoring the NCT02918032 clinical trial?
NCT02918032 is sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. The principal investigator is Kenichi Hirano, MD, Ph.D at Department of Cardiovascular Medicine, Faculty of Internal Medicine, Graduate School of Osaka University. The trial plans to enroll 120 participants.